Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

Core Viewpoint - Sobi has entered into a definitive agreement to acquire Arthrosi Therapeutics, enhancing its gout treatment pipeline with pozdeutinurad, a next-generation oral URAT1 inhibitor currently in Phase 3 trials [1][2][3] Company Overview - Sobi is a global biopharma company focused on rare diseases, employing approximately 1,900 people and generating SEK 26 billion in revenue in 2024 [10] - Arthrosi Therapeutics is a private late-stage biotechnology company based in San Diego, CA, specializing in pozdeutinurad for gout treatment [6] Acquisition Details - The acquisition involves an upfront payment of USD 950 million (approximately SEK 9.1 billion) and potential additional payments of up to USD 550 million (approximately SEK 5.3 billion) based on clinical, regulatory, and sales milestones [3][4] - The transaction is expected to close in the first half of 2026, subject to customary closing conditions [3] Product Information - Pozdeutinurad (AR882) is an investigational URAT1 inhibitor aimed at treating progressive and tophaceous gout, having shown compelling efficacy in Phase 2 studies [5] - It is currently being evaluated in two fully enrolled Phase 3 studies, with pivotal data expected in 2026 [5] Strategic Implications - The acquisition is anticipated to significantly enhance Sobi's growth trajectory and margin potential, with pozdeutinurad positioned as a therapy of choice for patients inadequately treated by first-line therapies [2][4]